Genomma Lab Internacional Sab De Cv Class B · BMV:LAB/B
Genomma Lab Internacional Sab De Cv Class B — Q3 2025 Earnings Presentation
26 slides from Genomma Lab Internacional Sab De Cv Class B's earnings presentation, October 2025
Slide 1: Genomma Lab Investor Relations
Genomma Lab.°® Internacional GENOMMA LAB INVESTOR RELATIONS
Slide 2: Forward-looking statements disclaimer
This presentation may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limit
Slide 3: About Genomma Lab
ABOUT GENOMMA LAB GENOMMA LAB pevetops, MANUFACTURES AND MARKETS A PORTFOLIO OF 60 PREMIUM BRANDED PRODUCTS FOR MASS CONSUMPTION, MANY OF WHICH ARE LEADERS IN THEIR CATEGORIES BUSINESS UNITS REGIONS 43% 48% 34% 48% Po ote S MEXICO gis a BEVERAGES
Slide 4: Healthy product mix: over-the-counter medicines
HEALTHY PRODUCT MIX OVER-THE-COUNTER MEDICINES COUGH & COLD ANALGESICS DERMA OTC
Slide 5: Healthy product mix: personal care
HEALTHY PRODUCT MIX PERSONAL CARE SKINCARE HAIRCARE ( Ver = Fy od ile OTHER
Slide 6: Healthy product mix: beverages
HEALTHY PRODUCT MIX BEVERAGES yw * . y } Siierc. SUER(, SUEROX ‘UcROX)SUERO “SUEROX;SUERO oRMULAHIDRATA FORMULAHIDRATANTE OR
Slide 7: Net sales and EBITDA in MXN million
$18,607 $18,190 $4,270 $4,276 $16,820 $16,467 $15,460 $13,870 $3,453 $3,386 $3,210 $12,713 $2,923 $2,472 2019 2020 2021 2022 2023 2024 LTM 2019 2020 2021 2022 2023 2024 LTM Q3 2025 Q3 2025 Net Sales in MXN million EBITDA in MXN million net of discontinued operation effects
Slide 8: Gross margin by quarter
65.3% 64.0% 64.3% 63.9% 63.1% 62.4% 63.5% 62.8% 61.4% 61.0% 59.9% 56.9% Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2022 2023 2023 2023 2023 2024 2024 2024 2024 2025 2025 2025
Slide 9: EBITDA margin by quarter
23.7% 23.8% 23.8% 22.9% 23.7% 22.8% 22.3% 21.3% 21.0% 21.1% 20.6% 20.6% 20.8% 19.9% 18.9% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2022 2022 2022 2022 2023 2023 2023 2023 2024 2024 2024 2024 2025 2025 2025 Net of discontinued operation effects
Slide 10: Quarterly margin trend
16.5% 15.9%15.9% 15.3% 14.5% 14.4% 13.9% 13.7% 13.7%13.6% 13.6% 13.5%13.5%13.5% 13.4% 12.6% 11.5% 11.2%11.3% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 2021 2021 2021 2022 2022 2022 2022 2023 2023 2023 2023 2024 2024 2024 2024 2025 2025 2025
Slide 11: Successful transformation over the past decade
Successful transformation over the past decade, transitioning from a deep restructuring phase into a growing and more profitable & capable company +69% +141% +152% +46%
Slide 12: Operating in a USD 13-trillion industry
Operating in a USD 13-trillion industry, Genomma Lab has overcome high entry barriers and is strategically positioned to expand its market share Brand Heritage Top Talent Robust Distribution Network Integrated Speed & Agility U.S. Hispanic and Manufacturing Brazilian Footprint
Slide 13: Business highlights
BUSINESS HIGHLIGHTS ~~ Sd 2H 2025 Resilient Productivity Top-line Headwinds Margin for Growth Growth Investing in: Innovation cape $2.2 billion -2% to -5% “24% $3 billion LFL Sales EBITDA margin Accumulated Go-to-market Savi by 2026 ous ®Y $1.9 billion $141 billion — Emerging channels Productivity i
Slide 14: Productivity for growth
PRODUCTIVITY FOR GROWTH LAUNCHING AN ADDITIONAL MXN +1 BILLION SAVINGS PROJECT TO BOOST SALES & MAINTAIN AN AVERAGE 24% EBITDA MARGIN Amounts in MXN millions coe +1,107 million Additional savings by 2026 $1,878 $388 2023 2024 2026E Realized productivity Productivity pipeline
Slide 15: Re-investing in growth projects
RE-INVESTING INGROWTH PROJECTS RE-INVESTING EXCESS CASH & PRODUCTIVITY IN KEY PROJECTS 2026-2027 Opportunity Size Price @ Product innovation 9 E-commerce 7% Go-to-market & a Traditional channel \ , Distribution 15% / 28% [) Ecommerce = Discounters + Convenience ~ Product innovation 32% Potential inc
Slide 16: Product innovation opportunities by business unit
Skincare Haircare Beverages OTC • Democratizing • Improved clean • New forms • 25 pharma registrations high-end skin performance to be approved by 2026 • Clean formulas & • Expanded routine • Renewed image fresh design • Conquering new • Increasing segments across • Driving trade up & consumption oc
Slide 17: Multimedia reach and social commerce
Multumedia Reach Social Commerce / Optimized Influencers Production • +25% reach vs traditional • Mass micro influencers & • Digital native assets & user vehicles brand embassadors generated content • Improved media mix to • Driving traffic to e-commerce • AI generated content reach targeted audienc
Slide 18: Traditional channel distribution expansion
TRADITIONAL CHANNEL DISTRIBUTION EXPANSION Mexico + Latam traditional channel sales Sales in MXN Millions +2.2M POS Universe +320k Additional POS by 2027 $1,910 M Incremental sales 2026-2027 +18% 2023 2024 2025E 2026E CAGR Latam 2-year project
Slide 19: E-commerce
E-COMMERCE ACCELERATING TRAFFIC & EXPANDING DIGITAL PRESENCE E-commerce sales Sales in MXN$ Millions $820 M Incremental sales 2026-2027 +30% CAGR 2-year project 2025E 2026E 2027E
Slide 20: 60k 55k 50k 45k 40k 35k 30k 25k 20k
60k 55k 50k 45k 40k 35k 30k 25k 20k
Slide 21: 25,0 20,0 15,0 10,0 5,00 -
25,0 00 20,0 00 15,0 00 10,0 00 5,00 0 -
Slide 22: There is more to conquer
THERE IS MORE TO CONQUER OUR GROWING MARKET SHARES HAVE A HUGE POTENTIAL Beverages Personal Care oTCc Including Brazil Infant Nutrition SHARE OF MARKET Mexico + Latam 5.3% 2.8% 8.2% 5.3% 1.4% CATEGORY SIZE Mexico + Latam US$ 2.4 billion US$ 10.5 billion US$ 4.9 billion US$8.0 billion US$ 24 billion
Slide 23: Innovation launches by brand
BU Brand Better Fresh Increased Expanded New New New New Int. Estimated Formula design routine use / dem forms functions sizes category Roll-out launch Skincare CICA ✓ ✓ ✓ ✓ ✓ ✓ ✓ Q3 2026 TTCAL ✓ ✓ ✓ ✓ ✓ ✓ ✓ Q2 2026 ASPX ✓ ✓ ✓ ✓ ✓ ✓ ✓ Q2 2026 Haircare TN ✓ ✓ ✓ ✓ ✓ ✓ ✓ Q2 2026 VRT ✓ ✓ ✓ ✓ Q3 2026 OTC
Slide 24: Strengthening OTC innovation pipeline
STREGTHENING OTC INNOVATION PIPELINE STRONG OTC REGISTRIES MOMENTUM: SUBMITTED REGISTRIES SINCE 2023 NOW APPROACHING APPROVAL STAGE Submitted OTC registries 98 ' 2022 2023 2024 126
Slide 25: Capital allocation priorities
CAPITAL ALLOCATION PRIORITIES 1. INVEST IN THE CORE BUSINESS ¢ Product innovation ¢ Go-to-market & distribution ¢ E-commerce ¢ Communication 2. TOTAL SHAREHOLDER RETURN ¢ $800 million annual dividend priority * Strategic buybacks
Slide 26: Genomma Lab
Genomma Lab.°® GENOMMA LAB
Genomma Lab Internacional — Q3 2025 Earnings Presentation on 6ix